Related Experiment Videos
Conserved delta-activity in reverse enantiomeric opioid peptide
1Osaka University of Pharmaceutical Sciences, Japan.
Life Sciences
|January 1, 1995
Summary
Reverse enantiomeric peptides, like those derived from Leu-enkephalin and DADLE, show specific affinity for delta-opioid receptors. This suggests receptor binding relies on peptide side chains rather than sequence or chirality.
Area of Science:
- Biochemistry
- Pharmacology
- Molecular Biology
Background:
- Peptide structure and chirality significantly influence biological activity.
- Reverse enantiomeric peptides are synthesized with reversed amino acid sequences and enantiomeric residues.
- Changes in peptide sequence or chirality often lead to altered receptor interactions.
Purpose of the Study:
- To investigate the receptor binding properties of reverse enantiomeric peptides.
- To determine the role of amino acid sequence and chirality in opioid receptor recognition.
- To explore the structural basis for delta-opioid receptor selectivity.
Main Methods:
- Synthesis of reverse enantiomeric peptides.
- Radioligand binding assays to assess receptor affinity.
- Comparison of binding affinities for mu, delta, and kappa opioid receptors.
Main Results:
- Reverse enantiomeric peptides of Leu-enkephalin and Tyr-D-Ala-Gly-Phe-D-Leu (DADLE) exhibited affinity for the delta-opioid receptor.
- These peptides did not show significant affinity for mu- or kappa-opioid receptors.
- Similar side-chain conformations were observed between native peptides and their reverse enantiomers.
Conclusions:
- Delta-opioid receptor recognition is primarily mediated by peptide side chain interactions.
- The specific sequence and chirality of opioid peptides are less critical for delta-receptor binding than side chain presentation.
- Reverse enantiomeric peptides can serve as valuable tools for understanding opioid receptor pharmacology.